AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05069506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goat milk as test food
Description: Twelve subjects (male: 4 female: 8) consumed 617 g goat milk yogurt, offering 25g available carbohydrate along with 250 mL water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
Study NCT05069506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goat milk and currants as test food
Description: Twelve subjects (male: 4 female: 8) consumed 308 g goat milk yogurt and 19 g currants, offering 25g available carbohydrate along with 250 mL water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
Study NCT05069506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Currants as test food
Description: Twelve subjects (male: 4 female: 8) consumed 37.8 g currants, offering 25g available carbohydrate along with 250 mL water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
Study NCT05069506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sultanina raisins as test food
Description: Twelve subjects (male: 4 female: 8) consumed 37.5 g sultanina raisins, offering 25g available carbohydrate along with 250 mL water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
Study NCT05069506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goat milk yogurt as preload
Description: Forty-five healthy subjects (male: 12, female: 33) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (200g goat milk yogurt). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate vanilla cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
Study NCT05069506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk with lactic acid as preload
Description: Forty-five healthy subjects (male: 12, female: 33) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (200g milk with lactic acid). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate vanilla cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
Study NCT01626898 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOLA en Grupos
Description: HOLA en Grupos consists of four 4-hour group sessions that combine presentations by facilitators who are trained Latino MSM community members, activities, and scenes from a DVD, and is delivered over a period of two weeks to groups of about 10 participants. HOLA en Grupos is designed to increase HIV prevention knowledge, condom use and mastery, decrease barriers to risk reduction (e.g., health-compromising aspects of machismo), enhance sexual negotiation skills, and increase use of HIV testing, counseling, and treatment services among intervention participants.
Study NCT01626898 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health intervention (comparison intervention )
Description: The Spanish comparison condition consists of four Spanish-language 4-hour group sessions designed to increase participants' knowledge about cancer, diabetes, alcohol abuse, and cardiovascular disease, and is delivered over a period of two weeks to groups of about 10 participants.
Study NCT04638348 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: New Biofeedback
Description: Conventional biofeedback consists of a electromyography biofeedback device with a vaginal probe.
Study NCT04638348 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New Biofeedback
Description: Conventional biofeedback consists of a electromyography biofeedback device with a vaginal probe.
Study NCT01616420 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assisted-partner notification services
Description: Assisted-partner notification services (aPS) is a public health service which notifies the partners of those who test positive for a communicable disease of their exposure.
Study NCT02618655 — intervention group
Intervention type: OTHER
Intervention: diagnostic methods
Description: explore several laboratory diagnostic methods to find out which will be more helpful for making an accurate diagnosis in the early period of TBDs.
Study NCT04173689 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Threshold IMT
Description: 7 days a week, 2 times a day 15 min each
Study NCT04173689 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: breathing exercises combined with upper extremity and trunk
Description: upper extremity and trunk exercises combined with breathing exercises for 7 days a week, 2 times a day for 15 minutes each
Study NCT00471705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine
Description: Miltefosine 2.5 mg/Kg/day with a maximum dose of 150 mg PO day.
Study NCT00471705 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermotherapy
Description: One session of local heat using a thermotherapy device at 50 celsius degrees during 30 seconds.
Study NCT00471705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucantime®
Description: Glucantime® 20 mg /Kg /day for 20 days (intramuscular)
Study NCT03117075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: using device for scoring pain scale, named ANAPA®
Description: wearable device for scoring pain scale
Study NCT04452474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olokizumab 64 mg
Description: solution for subcutaneous administration 160 mg/mL
Study NCT04452474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline (0.9% Sodium Chloride solution for Injection), in the market package
Study NCT04802525 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise training
Description: The first group has received Moderate-intensity aerobic exercise training without dietary control, the second group has received a low-fat diet program without exercise intervention, and the third group has received Moderate-intensity aerobic exercise training plus a low-fat diet program for 10 consecutive weeks
Study NCT03215420 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI 3T
Study NCT04080570 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Visit
Description: After an initial in-home visit, the physician will see home hospitalized patients by facilitated video.
Study NCT00585000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-675,206
Description: 15 mg/kg. IV (in the vein) over 1 hour on Day 1 of each 90 day cycle. Number of cycles: maximum of 4 cycles unless progression of disease or unacceptable toxicity.
Study NCT02554903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan 10mg
Description: 2 groups, randomized in a 1:1 ratio by an Interactive Voice/Web Randomization System to macitentan 10 mg or placebo
Study NCT02554903 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sugar pill
Description: 2 groups, randomized in a 1:1 ratio by an Interactive Voice/Web Randomization System to macitentan 10 mg or placebo
Study NCT02776189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: intravenous dexmedetomidine 1 mcg per kg body weight over 10 minutes followed by infusion of dexmedetomidine at dose of 1 mcg per kg body weight per hour till end of procedure
Study NCT02776189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: intravenous propofol 2mg per kg body weight followed by infusion of propofol at a dose of 100 mcg per kg body weight per min till end of procedure
Study NCT02776189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Intra nasal midazolam 0.2 mg per kg body weight before intravenous canulation
Study NCT02776189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Intra nasal midazolam 0.2 mg per kg body weight before intravenous canulation
Study NCT04168073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-sodium diet 300 mmol sodium/day
Description: Day 7 or day 21 high-sodium diet begins for 8 days. Day 15 wash-out begins for 6 days. Pre-made meals for both the high-and low-sodium diet will be provided to each participant by the study team.
Study NCT04168073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-sodium diet 10 mmol sodium/day
Description: Day 7 or day 21 low-sodium diet begins for 8 days. Day 15 wash-out begins for 6 days. Pre-made meals for both the high-and low-sodium diet will be provided to each participant by the study team.
Study NCT02934308 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skin Conductance Monitor
Study NCT03492528 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples
Description: blood samples
Study NCT03378323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multiple injection local anesthetic
Description: Multiple injection local anesthetic
Study NCT03378323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single injection local anesthetic
Description: Single injection local anesthetic
Study NCT02975427 — intervention group
Intervention type: OTHER
Intervention: Diet group
Description: All participants were prescribed an appropriate diet with caloric restriction and an exercise program and underwent a follow-up examination 3±1 months later.
Study NCT02867176 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gabapentin
Description: The gabapentin (Neurontin, Pfizer, Mexico) group was instructed to take one 300-mg capsule the night before surgery and 1 capsule every 8 hours on the day of surgery and for the first 3 postoperative days.
Study NCT02867176 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ketorolac
Description: The ketorolac group (Dolac, Siegfried Rhein, Mexico) was instructed to take their 10-mg tablets every 8 hours on the day of surgery and for the first 3 postoperative days.
Study NCT03777150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative care in Intensive care unit (ICU)
Description: Postoperative care in Intensive care unit (ICU)
Study NCT03777150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative care in standard ward
Description: Postoperative care in standard ward
Study NCT03610724 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Description: Tisagenlecleucel was infused once as an intravenous infustion at a dose of either 0.2 to 5 x 106 CAR-positive viable T cells per kg body weight for subjects ≤ 50 kg or 0.1 to 2.5 x 108 CAR-positive viable T cells for subjects > 50 kg.
Study NCT03610724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lymphodepleting chemotherapy
Description: Prior to tisagenlecleucel infusion, each subject underwent lymphodepletion with recommended Fludarabine and cyclophosphamide (unless contra-indicated for subject)
Study NCT03610724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bridging Therapy
Description: Pre-treatment phase could also include bridging therapy of investigator's choice
Study NCT03665389 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: iFR / FFR measurement
Description: At the time of pre-TAVR coronary angiogram, iFR (iFR before TAVR) will be measured. The cCTA data collected from patients whose consent is obtained following TAVR will be anonymized and sent to HeartFlow, Inc., where the FFRct （FFRct before TAVR） values will be calculated using their cardiovascular dynamics analysis program. With the FFRct values blinded, FFR (FFR after TAVR) and iFR (iFR after TAVR) will be measured using a guide wire that is capable of sensing pressure after TAVR is performed. Furthermore, FFRct(FFRct after TAVR) is calculated from cCTA taken after TAVR.
Study NCT05069883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid Drug
Description: In this group Oral steroid medication after Direct Vision Internal Urethrotomy
Study NCT05069883 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: No steroid
Description: In this group no Oral steroid medication (palcebo medication) after Direct Vision Internal Urethrotomy
Study NCT03663426 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: study group
Description: 1. High dose corticoids pre-operative and 24h postoperative~2. Opioid free general anesthesia~3. Avoid opioids post-operative by continue clonidine, ketamine and lidocaine, only exceptional opioids after NSAID and paracetamol.
Study NCT03663426 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: 1. No corticoids pre-operative.~2. Opioid anesthesia~3. Opioids post-operative after NSAID and paracetamol.
Study NCT01015768 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReNu Multiplus multipurpose disinfecting solution
Description: A new lens (PureVision) soaked 6 hours to overnight in ReNu Multiplus
Study NCT01015768 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: A new lens (PureVision) is soaked for two hours in non-preserved saline
Study NCT01561950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eptacog alfa (activated)
Description: If subject is eligible to continue after clopidogrel treatment, three different doses of trial drug is administered i.v. as a slow bolus injection over two to three minutes followed by post-trial biopsies
Study NCT01561950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: Following a baseline biopsy (B0) subjects will receive oral treatment with an initial 300 mg loading dose followed by daily 75 mg doses for at least 3 additional days. If the target platelet inhibition (PI) is achieved, the subject will undergo punch biopsy 1 (B1).
Study NCT01561950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: clopidogrel
Description: Following a baseline biopsy (B0) subjects will receive oral treatment with an initial 300 mg loading dose followed by daily 75 mg doses for at least 3 additional days. If the target platelet inhibition (PI) is achieved, the subject will undergo punch biopsy 1 (B1).
Study NCT01561950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: If subject is eligible to continue after clopidogrel treatment, three different doses of trial drug is administered i.v. as a slow bolus injection over two to three minutes followed by post-trial biopsies
Study NCT00754793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: 10mg - 30mg daily titrated as tolerated over 12 weeks
Study NCT00754793 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: inactive comparator; titrated as per protocol over 12 weeks
Study NCT05395611 — intervention group
Intervention type: OTHER
Intervention: EBPcollected using the PExA device.
Description: The PExA device is a non invasive device that collect particles in exhaled air
Study NCT00742248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: pMDI 12 mcg/dose 1 dose in the morning and 1 dose in the evening
Study NCT00742248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: DPI 12 mcg/dose 1 dose in the morning and 1 dose in the evening
Study NCT00742248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo pMDI/DPI 1 dose in the morning and 1 dose in the evening
Study NCT00742248 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pMDI/DPI 1 dose in the morning and 1 dose in the evening
Study NCT00318214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRE0094
Description: Gel, 500 mcg/g once each day
Study NCT00318214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Description: Gel administered once per day
Study NCT01395875 — intervention group
Intervention type: DRUG
Intervention: Fluticasone Propionate / Salmeterol Xinafoate Combination (FSC)
Description: COPD patients receiving fluticasone propionate/salmeterol xinafoate combination (FSC) 250/50mcg
Study NCT01395875 — intervention group
Intervention type: DRUG
Intervention: Anticholinergics (AC)
Description: COPD patients receiving anticholinergics (ACs) including tiotropium (TIO) and ipratropium or combination ipratropium-albuterol (collectively referred to as ipratropium \[IPR\]).
Study NCT00063570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2, intravenous (IV), every 14 days, until disease progression
Study NCT00063570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1500 mg/m2, intravenous (IV), every 14 days, until disease progression
Study NCT00063570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2, intravenous (IV), on Days 1 and 8 of 21-day cycle, until disease progression
Study NCT00063570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2, intravenous (IV), every 21 days, until disease progression
Study NCT01147744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate 100mcg via ACCUHALER/DISKUS
Description: Fluticasone propionate 100mcg twice daily via ACCUHALER/DISKUS
Study NCT01147744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 100mg
Description: GSK2190915 100mg (1 x 100mg) once daily in the morning
Study NCT01147744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 10mg
Description: GSK2190915 10mg (1 x 10mg) once daily in the morning
Study NCT01147744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 300mg
Description: GSK2190915 300mg (1 x 100mg, 1 x 200mg tablets) once daily in the morning
Study NCT01147744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190915 30mg
Description: GSK2190915 30mg (1 x 30mg) once daily in the morning
Study NCT01147744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast 10mg
Description: Montelukast 10mg (1 x 10mg capsule) once daily in the evening
Study NCT01147744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo GSK2190915 one tablet
Description: Placebo tablet, one tablet once daily in the morning
Study NCT01147744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo montelukast
Description: Placebo capsule once daily in the evening
Study NCT01147744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo montelukast
Description: Placebo capsule once daily in the evening
Study NCT01147744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo montelukast
Description: Placebo capsule once daily in the evening
Study NCT01147744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo fluticasone propionate via ACCUHALER/DISKUS
Description: Inhaled placebo twice daily via ACCUHALER/DISKUS
Study NCT01147744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo fluticasone propionate via ACCUHALER/DISKUS
Description: Inhaled placebo twice daily via ACCUHALER/DISKUS
Study NCT01147744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo fluticasone propionate via ACCUHALER/DISKUS
Description: Inhaled placebo twice daily via ACCUHALER/DISKUS
Study NCT01147744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo GSK2190915 two tablets
Description: Placebo tablet, two tablets once daily in the morning
Study NCT01147744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo GSK2190915 two tablets
Description: Placebo tablet, two tablets once daily in the morning
Study NCT04123236 — intervention group
Intervention type: OTHER
Intervention: Age 0-18
Description: Patients under 18 years of age
Study NCT04123236 — intervention group
Intervention type: OTHER
Intervention: Age 18-26
Description: Patients over18 years of age
Study NCT04123236 — intervention group
Intervention type: OTHER
Intervention: Girls
Description: Girls
Study NCT04123236 — intervention group
Intervention type: OTHER
Intervention: Boys
Description: Boys
Study NCT04474665 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Reverse shoulder arthroplasty utilizing Blueprint Software
Description: Reverse shoulder arthroplasty utilizing Blueprint Software